Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor
about
Advancements in the Management of HPV-Associated Head and Neck Squamous Cell CarcinomaQuantification of secretory leukocyte protease inhibitor (SLPI) in oral gargle specimens collected using mouthwashGeographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trialsSmall molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection.Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidantsHerpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort.SLPI and AnxA2 expression in neoplasm-free palatine tonsils is associated with smoking habit of individuals.Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations.T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation.Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients.Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions.miRNA-expression in tonsillar squamous cell carcinomas in relation to HPV infection and expression of the antileukoproteinase SLPI.Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol.Smoking-Induced SLPI Expression Hinders HPV Infections Also in Squamous Cell Carcinomas of the Vulva
P2860
Q26799543-C99D9031-8337-4DA5-B7C2-800F7AC357BBQ28300527-547EDB6E-F38F-47FD-9B0E-C3FF2D52CFA8Q31036080-A5C1EB45-6648-45A9-91DF-F598BEC75CDEQ35662068-05C9C31F-0EB6-4E7F-AC55-8863958C651BQ36104532-A5CB6540-A58B-4EA7-9F62-49D430BAA5BFQ36720700-82E480F4-25B4-40DE-A323-DC530D4A089DQ36731195-4E78F26A-B8B9-4D67-811B-BD8B3CE30CFCQ38622805-1F78EB94-FCEE-4224-878A-1451936E256EQ39547383-13F2D006-CE46-4D98-BCA5-D46AAEFFF4EEQ40673637-999F0C18-FB1D-4259-B14A-79E4FC441567Q40686286-4D7BC6B0-AA9E-410C-B08D-E5CFADE8B339Q45934714-C94D1FDC-02FC-463A-A804-ACB4BD3203B1Q47359848-4D42A33E-D0F1-4B1B-AA5C-D8D024557896Q50065081-A803FD3A-F33A-428C-BA87-6F49B2F87B16Q57149787-F815A47C-ABBA-424B-B9C0-FB72EA2D0BC0
P2860
Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Human papillomavirus infection ...... y leukocyte protease inhibitor
@ast
Human papillomavirus infection ...... y leukocyte protease inhibitor
@en
Human papillomavirus infection ...... y leukocyte protease inhibitor
@nl
type
label
Human papillomavirus infection ...... y leukocyte protease inhibitor
@ast
Human papillomavirus infection ...... y leukocyte protease inhibitor
@en
Human papillomavirus infection ...... y leukocyte protease inhibitor
@nl
prefLabel
Human papillomavirus infection ...... y leukocyte protease inhibitor
@ast
Human papillomavirus infection ...... y leukocyte protease inhibitor
@en
Human papillomavirus infection ...... y leukocyte protease inhibitor
@nl
P2093
P2860
P50
P356
P1433
P1476
Human papillomavirus infection ...... y leukocyte protease inhibitor
@en
P2093
Anna R Giuliano
Elgar S Quabius
Gordana Halec
Jochen Haag
Jürgen Hedderich
Lena Hebebrand
Markus Hoffmann
Silke Tribius
Tibor Görögh
Tomas Kahn
P2860
P304
P356
10.3892/OR.2013.2327
P407
P577
2013-05-01T00:00:00Z